Skip to Content

Updated results on AVO therapeutic triplet regimen in untreated patients with CLL

In this MEDtalk, MD Christine Ryan presents updated results from a multicenter phase 2 study investigating the effects of acalabrutinib, venetoclax, and obinutuzumab (AVO) combination in patients with previously untreated CLL. The study suggests AVO as a highly active triplet combination for this group of patients, also the once enriched for high-risk disease. AVO is currently undergoing investigation in a phase 3 study as well.

Christine Ryan

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top